No Data
No Data
China Resources Pharmaceutical (03320.HK): Jiangzhong Pharmaceutical's net profit of 267 million yuan in the first quarter increased 9.99% year-on-year
Gelonghui, April 29丨China Resources Pharmaceutical (03320.HK) announced that Jiangzhong Pharmaceutical (600750.SH) achieved operating income of 1,227 billion yuan in the first quarter of 2024, down 8.74% year on year; net profit attributable to shareholders of listed companies (Jiangzhong Pharmaceutical) was 267 million yuan, up 9.99% year on year; net profit attributable to shareholders of listed companies (Jiangzhong Pharmaceutical) after deducting non-recurring profit and loss was 264 million yuan, up 16.64% year on year.
Jiangzhong Pharmaceutical (600750.SH) reported first-quarter results with net profit of 267 million yuan, up 9.99% year on year
According to the Zhitong Finance App, Jiangzhong Pharmaceutical (600750.SH) released its report for the first quarter of 2024, achieving revenue of 1,227 billion yuan, a year-on-year decrease of 8.74%. Net profit attributable to shareholders of listed companies was 267 million yuan, an increase of 9.99% over the previous year. Achieved net profit of 264 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 16.64% over the previous year.
China Resources Pharmaceutical (03320.HK): Jiangzhong Pharmaceutical's net profit in 2023 increased by 708 million yuan year on year, up 18.4% year on year
Gelonghui, March 25, 丨 China Resources Pharmaceutical (03320.HK) issued an announcement. Jiangzhong Pharmaceutical (600750.SH) announced its 2023 annual report, with operating revenue of RMB 4.39 billion, up 13.00% year on year; net profit attributable to Jiangzhong Pharmaceutical shareholders of RMB 708 million, up 18.4% year on year; net profit attributable to shareholders of Jiangzhong Pharmaceutical (after deducting non-recurring income or loss) of 704 million yuan, an increase of 38.97% year on year; basic earnings per share were 1.12 yuan. A cash dividend of 7 yuan is distributed for every 10 shares.
Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Has Had A Decent Run On The Stock Market: Are Fundamentals In The Driver's Seat?
Jiang Zhong PharmaceuticalLtd's (SHSE:600750) stock is up by 6.7% over the past three months. We wonder if and what role the company's financials play in that price change as a company's long-term f
China Resources Pharmaceutical: Jiangzhong Pharmaceutical expects net profit to increase by about 18% year-on-year in 2023
China Resources Pharmaceutical (03320) issued an announcement. According to preliminary accounting by Jiangzhong Pharmaceutical (600750.SH), in 2023, Jiangzhong Pharmaceutical's total revenue increased by about 13% year on year; net profit attributable to shareholders of Jiangzhong Pharmaceutical increased by about 18% year on year.
Damo: Target price of HK$7.8 for China Resources Pharmaceuticals “gain” rating
Damo released a research report stating that it is believed that the stock price of China Resources Pharmaceuticals (03320) will rise within 30 days, the rating will “increase”, and the target price is HK$7.8. Donga Ejiao (000423.SZ) and Jiangzhong Pharmaceutical (600750.SH), of the five A-share subsidiaries directly under China Resources Pharmaceutical, announced new management incentive plans, all in the form of restricted shares, and both cover profit performance from 2022 to 2026. The bank believes that the management incentive plans of the two companies reflect current expectations that there is room for improvement.
No Data